274 related articles for article (PubMed ID: 28106924)
1. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
Classe M; Malouf GG; Su X; Yao H; Thompson EJ; Doss DJ; Grégoire V; Lenobin J; Fantoni JC; Sudour-Bonnange H; Khayat D; Aubert S; Tannir NM; Leroy X
Histopathology; 2017 Jun; 70(7):1089-1097. PubMed ID: 28106924
[TBL] [Abstract][Full Text] [Related]
2. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
3. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
[TBL] [Abstract][Full Text] [Related]
4. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
[TBL] [Abstract][Full Text] [Related]
5. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
6. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
[TBL] [Abstract][Full Text] [Related]
8. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
9. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
[TBL] [Abstract][Full Text] [Related]
10. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.
Just PA; Letourneur F; Pouliquen C; Dome F; Audebourg A; Biquet P; Vidaud M; Terris B; Sibony M; Pasmant E
Genes Chromosomes Cancer; 2016 Jun; 55(6):541-8. PubMed ID: 26998913
[TBL] [Abstract][Full Text] [Related]
11. [The translocation carcinoma: A pediatric renal tumor also in adults].
Bruder E; Moch H
Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
[TBL] [Abstract][Full Text] [Related]
12. Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.
Liu N; Wang Z; Gan W; Xiong L; Miao B; Chen X; Guo H; Li D
PLoS One; 2016; 11(11):e0166897. PubMed ID: 27893792
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
14. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
[TBL] [Abstract][Full Text] [Related]
16. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
17. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
Neha ; Das P; Verma SP
Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
[TBL] [Abstract][Full Text] [Related]
18. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
19. A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
Ye H; Qin S; Li N; Lin M; Xu Y; Li X
Biomed Res Int; 2019; 2019():5974089. PubMed ID: 31828108
[TBL] [Abstract][Full Text] [Related]
20. Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.
Cao C; Lan X; Shang B; Jiang W; Guo L; Zheng S; Bi X; Zhou A; Sun Z; Shou J
Clin Transl Oncol; 2022 Jul; 24(7):1333-1346. PubMed ID: 35118587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
